Takeda Pharmaceutical Co. $TAK Shares Sold by HighTower Advisors LLC

Key Points

• HighTower Advisors LLC has reduced its stake in Takeda Pharmaceutical by 29.5%, selling 36,694 shares to end with 87,745 shares valued at approximately $1.3 million.
• Other institutional investors showed mixed activity, with GAMMA Investing LLC increasing its holdings by 22.6%, while Zacks Research downgraded the stock from a "hold" to a "strong sell" rating.
• Takeda Pharmaceutical reported a net margin of 3.20% and a return on equity of 10.50% for its recent quarter, beating earnings estimates but falling short on revenue projections.

HighTower Advisors LLC lessened its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 29.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 87,745 shares of the company's stock after selling 36,694 shares during the quarter. HighTower Advisors LLC's holdings in Takeda Pharmaceutical were worth $1,305,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of TAK. GAMMA Investing LLC lifted its position in Takeda Pharmaceutical by 22.6% in the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after purchasing an additional 1,296 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Takeda Pharmaceutical by 5.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company's stock worth $319,000 after acquiring an additional 1,098 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after acquiring an additional 1,045 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of Takeda Pharmaceutical during the first quarter valued at $262,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Takeda Pharmaceutical by 60.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock valued at $2,409,000 after buying an additional 68,200 shares during the last quarter. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

NYSE TAK traded up $0.12 during trading on Thursday, hitting $14.98. 2,721,240 shares of the stock traded hands, compared to its average volume of 4,146,209. The company has a market capitalization of $47.65 billion, a P/E ratio of 49.92 and a beta of 0.22. The firm has a 50-day simple moving average of $14.80 and a 200-day simple moving average of $14.72. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $15.56.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion during the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold".

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.